MFN2 and Charcot-Marie-Tooth disease type 2A1: The majority of confirmed CMT2A patients have mutations within the MFN2 GTPase domain presumed to impair catalytic GTPase activity essential to mitochondrial fusion (although actual biochemical GTPase inactivity has only been demonstrated in select GTPase domain mutations).